Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

The US Food and Drug Administration (FDA) has accepted Regeneron Pharmaceuticals’ supplemental biologics licence application (sBLA) for Eylea HD (aflibercept) injection 8mg for priority review.

Regeneron (REGN) stock drops as the company's Q1 2025 results miss forecasts amid disappointing sales from its blockbuster ...

“Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation EYLEA HD ® (aflibercept) Injection 8 mg; uncertainty of the ...

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... for EYLEA HD ® (aflibercept) Injection 8 mg across all approved indications. The CRL did not identify any ...